Chordomas are very rare malignant tumors, chemo-resistant with high propensity for recurrence. The role of immunotherapy in these patients remains largely unexplored while PD-L1 and CD8 status in the micro-environment of chordomas is basically not known. Similarly, this tumor often poses diagnostic difficulties due to its resemblance with metastasis or chondrosarcoma, thus, it would be useful to know the expression status of factors used during the work-up of metastatic or mesenchymal tumors, like CDX2, INSM1 and FOXA1, which remains unknown for chordomas. Thus, the aim of the study is to explore PD-L1, CD8, CDX2, INSM1 and FOXA1 expression in a series of chordomas and compare it with clinico-pathological and prognostic features.
Retrospective, non-interventional study. A series of chordomas will be analyzed for detailed histologic features and for various immunohistochemical factors and results will be compared with clinical factors, like overall and disease-free survival.
Study Type
OBSERVATIONAL
Enrollment
40
Analysis of histological material for immunohistochemical study. To explore PD-L1, CD8, CDX2, INSM1 and FOXA1 expression
CHU de Saint-Etienne
Saint-Etienne, France
Expression of PD-L1
measured by immunohistochemical method
Time frame: Baseline
Expression of CD8
measured by immunohistochemical method
Time frame: Baseline
Expression of CDX2
measured by immunohistochemical method
Time frame: Baseline
Expression of INSM1
measured by immunohistochemical method
Time frame: Baseline
Expression of FOXA1
measured by immunohistochemical method
Time frame: Baseline
Histological type of tumor
data collected in personal health records.
Time frame: Baseline
Tumor location
data collected in personal health records.
Time frame: Baseline
survival of patients after diagnosis with or without progression
data collected in personal health records.
Time frame: Baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.